FrieslandCampina has announced a partnership with US-based pharmaceutical group Glycosyn to produce ingredients for the infant nutrition market.
The two have signed a technology and partnership agreement. Glycosyn has developed a patented technology for the production of oligosaccharides from lactose. FrieslandCampina’s ingredients unit, Domo, will produce and introduce these new ingredients onto the global market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
John Garrett, co-CEO, at Glycosyn, said: “Human Milk Oligosaccharides (HMO’s) are specialised carbohydrates which are naturally prevalent in mother’s milk. Through our expertise and know-how we have developed technologies which will complement FrieslandCampina’s extensive history and knowledge of infant nutrition ingredients, products and markets.”
Tine Snels, executive director of FrieslandCampina Ingredients, added: “Glycosyn helps us to take a very exciting step towards developing the next generation of infant nutrition and to strengthen our position as a market leader in infant nutrition ingredients. We are doing this to meet the growing global demand for high-quality ingredients. Our cooperation is a perfect example of co-creation. The first quantities for trials will be available in the current year.”
